In the following video, Brenton Flynn sits down with Fool.com analyst Brendan Byrnes to discuss a topic that's gathered considerable attention in recent years: orphan drug development. In particular, they discuss the reasons for this focus, as well as an interesting scenario in which a very small patient market has become saturated with options.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.